pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

Boehringer Ingelheim Corp

updated 2mo ago

C.H. Boehringer Sohn AG & Co. KG is the parent company of the Boehringer Ingelheim group, which was founded in 1885 by Albert Boehringer (1861–1939) in Ingelheim am Rhein, Germany. As of 2018, Boehringer Ingelheim is one of the world's largest pharmaceutical companies, and the largest private one.

community read0 votes

🐶 often sniffed alongside

top 8
  • tagApproval222 co-mentions · 111 sources
  • drugTRIJARDY XR96 co-mentions · 89 sources
  • tagSmall Molecule96 co-mentions · 95 sources
  • drugSYNJARDY35 co-mentions · 35 sources
  • drugempagliflozin26 co-mentions · 26 sources
  • drugJARDIANCE26 co-mentions · 26 sources
  • drugCYLTEZO24 co-mentions · 12 sources
  • drugHUMIRA24 co-mentions · 12 sources
pipeline
27
marketed
20
phase 3
0
catalysts ytd
3
approvals ytd
3
recalls ytd
0

Pipeline(27)

view full pipeline →
pipeline depth27 products
Marketed: 20Unknown: 7
20Marketed7Unknown
Marketed
(empagliflozin + linagliptin + metformin hydrochloride) ER
Type 2 Diabetes
Marketed
(empagliflozin + linagliptin)
Type 2 Diabetes
Marketed
(empagliflozin + metformin hydrochloride ER)
Type 2 Diabetes
Marketed
(linagliptin + metformin hydrochloride) ER
Type 2 Diabetes
Marketed
(olodaterol hydrochloride + tiotropium bromide)
Chronic Bronchitis
Marketed
CYLTEZO
Marketed
Combivent Respimat
Bronchospasm
Marketed
LINAGLIPTIN
Type 2 Diabetes
Marketed
Micardis HCT
Hypertension
Marketed
Ofev
Systemic Sclerosis (Scleroderma)
Marketed
SYNJARDY
Cardiovascular Risk Factors
Marketed
Spiriva
Bronchospasm

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →
🐶 Hiring Signal
No open roles indexed yet — view Boehringer Ingelheim Corp jobs →

News

  • After billions in deals, Insilico CEO promises: ‘You haven't seen anything yet’
    Insilico Medicine CEO Alex Zhavoronkov’s mad dash across the BIO International Convention in June attracted plenty of eyes. But the executive would prefer industry watchers gawk at the billions of…
    biospace · 6h ago
  • A COPD drug from China draws $115M in venture funding
    Expedition Therapeutics, which has raised nearly $300 million to date, is studying a drug it believes to have notable advantages over other COPD treatments either in development or on the market.
    biopharma_dive · 6d ago
  • Chutes & Ladders—Legend CEO departs without successor in place
    Legend Biotech CEO Ying Huang, Ph.D., has left the company suddenly, without a predecessor in place. Huang was elevated from CFO to CEO in 2020 after a Chinese customs investigation was opened on f…
    fiercebiotech · 12d ago
  • ‘Reverse mergers are increasingly popular’: Caldera hops on Synlogic’s Nasdaq listing
    Caldera Therapeutics has struck a reverse merger with the publicly traded Synlogic and inked a $278 million financing deal, continuing the meteoric rise of the inflammatory bowel disease startup.
    fiercebiotech · 13d ago
  • Indian generics maker Lupin seeds US spinout Kaveri with cash, clinical-phase cancer assets
    Lupin has spun out two clinical-phase cancer drug candidates to create Kaveri Therapeutics, a U.S.-based startup that plans to raise cash for further development. Kaveri’s programs hit targets purs…
    fiercebiotech · 21d ago
  • How well are AI-discovered drugs faring in the clinic?
    Some of the industry’s most closely-watched AI drugs could provide insight into the success of technology-assisted development.
    biopharma_dive · 25d ago
  • Novartis cuts New Jersey jobs; OTR, LG Chem explore China cancer drugs
    Plus news about Seres, Biocytogen, Whitehawk, Boehringer Ingelheim, Prime Vector and MindRank. ⚠️ Novartis reduces New Jersey headcount: A WARN notice for the state notes that 322 employees in East…
    endpoints · 1mo ago
  • A PureTech startup banks $180M for a new IPF drug
    Celea, backed by investors such as RA Capital and Leaps by Bayer, is making what it says is an improved version of Roche's Esbriet.
    biopharma_dive · 1mo ago
  • STAT+: An obesity drug deep-dive, and peptides move mainstream
    Can any of the new obesity medications in development stand out from the pack? Which company just broke records with its IPO? And will the Food and Drug Administration allow…
    stat · 2mo ago
  • Major readouts from the annual diabetes conference
    Why "Schedule F" matters, the Ebola outbreak response, and more health news from Morning Rounds
    stat · 2mo ago
view all news mentions →
identifiers
source
globaldata
top tags
Type 2 Diabetes5Cardiology4Pulmonology4COPD3NSCLC2
mentioned in
10news items
entity-linker matched
Data sources
openFDA
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?